Author:
Li Na,Li Jia-Wei,Qian Yu,Liu Ya-Jing,Qi Xiu-Zhu,Chen Ya-Ling,Gao Yi,Chang Cai
Abstract
Abstract
Background
The purpose of this research is to study the sonographic and clinicopathologic characteristics that associate with axillary lymph node metastasis (ALNM) for pure mucinous carcinoma of breast (PMBC).
Methods
A total of 176 patients diagnosed as PMBC after surgery were included. According to the status of axillary lymph nodes, all patients were classified into ALNM group (n = 15) and non-ALNM group (n = 161). The clinical factors (patient age, tumor size, location), molecular biomarkers (ER, PR, HER2 and Ki-67) and sonographic features (shape, orientation, margin, echo pattern, posterior acoustic pattern and vascularity) between two groups were analyzed to unclose the clinicopathologic and ultrasonographic characteristics in PMBC with ALNM.
Results
The incidence of axillary lymph node metastasis was 8.5% in this study. Tumors located in the outer side of the breast (upper outer quadrant and lower outer quadrant) were more likely to have lymphatic metastasis, and the difference between the two group was significantly (86.7% vs. 60.3%, P = 0.043). ALNM not associated with age (P = 0.437). Although tumor size not associated with ALNM(P = 0.418), the tumor size in ALNM group (32.3 ± 32.7 mm) was bigger than non-ALNM group (25.2 ± 12.8 mm). All the tumors expressed progesterone receptor (PR) positively, and 90% of all expressed estrogen receptor (ER) positively, human epidermal growth factor receptor 2 (HER2) were positive in two cases of non-ALNM group. Ki-67 high expression was observed in 36 tumors in our study (20.5%), and it was higher in ALNM group than non-ALNM group (33.3% vs. 19.3%), but the difference wasn’t significantly (P = 0.338).
Conclusions
Tumor location is a significant factor for ALNM in PMBC. Outer side location is more easily for ALNM. With the bigger size and/or Ki-67 higher expression status, the lymphatic metastasis seems more likely to present.
Funder
National Nature Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO classification of tumours of the breast. 4th ed. Lyon: IARC; 2012.
2. Hashmi AA, Zia S, Yaqeen SR, Ahmed O, Asghar IA, Islam S, et al. Mucinous breast carcinoma: clinicopathological comparison with invasive ductal carcinoma. Cureus. 2021;13(3):e13650.
3. Marrazzo E, Frusone F, Milana F, Sagona A, Gatzemeier W, Barbieri E, et al. Mucinous breast cancer: a narrative review of the literature and a retrospective tertiary single-centre analysis. Breast. 2020;49:87–92.
4. Zhou XT, Zheng ZB, Li Y, Zhao WW, Lin Y, Zhang JS, et al. The clinical features and prognosis of patients with mucinous breast carcinoma compared with those with infiltrating ductal carcinoma: a population-based study. BMC Cancer. 2021;21(1):536.
5. Pan B, Yao R, Shi J, Xu QQ, Zhou YD, Mao F, et al. Prognosis of subtypes of the mucinous breast carcinoma in Chinese women: a population-based study of 32-year experience (1983–2014). Oncotarget. 2016;7(25):38864–75.